This opinion, however, is counter to the common clinical belief which is heavily influenced by the use of aprepitant (Emend) for chemotherapy-induced nausea and vomiting (CINV) [36, 37] and failed clinical trials with aprepitant [38] and other NK1R antagonists in depression. This evidence concerns the gene TACR1 and depressive symptom measurement.